Lynparza first in class approved in breast cancer
Impressed by survival data, FDA hastens review in expanded patient group
EU regulators recommend PARP inhibitor Zejula
Clovis’ Rubraca, the drug showing significant benefits for all ovarian cancer patients in a maintenance setting – and better results than its rivals.
Clovis and BMS research small molecule and antibody combination.
US biotech looks to bolster pipeline.
Company nabs maintenance therapy use, but problems on breast cancer trial.
UK firm lays down the gauntlet in the PARP inhibitor battle.
Clovis’ Rubraca will compete against AstraZeneca rival.
